Article
Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
BMC infectious diseases - 10 Jan 2020
Tsertsvadze Tengiz, Gamkrelidze Amiran, Nasrullah Muazzam, Sharvadze Lali, Morgan Juliette, Shadaker Shaun, Gvinjilia Lia, Butsashvili Maia, Metreveli David, Kerashvili Vakhtang, Ezugbaia Marina, Chkhartishvili Nikoloz, Abutidze Akaki, Kvaratskhelia Valeri, Averhoff Francisco
Abstract excerpt
BACKGROUND: Georgia has one of the highest HCV prevalence in the world and launched the world's first national HCV elimination programs in 2015. Georgia set the ambitious target of diagnosing 90% of people living with HCV, treating 95% of those diagnosed and curing 95% of treated patients by 2020. We report outcomes of Sofosbuvir (SOF) based treatment regimens in patients with chronic HCV infection in Georgia....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.